EuropaBio, the European Association for Bioindustries, today announces the finalists for 8th edition of the Most Innovative European Biotech SME Awards, which recognizes innovative biotech SMEs and the crucial role they play in answering some of society’s greatest challenges.
Twenty-five small and medium biotech companies contended for this year’s awards, with five of them shortlisted by the Jury to compete across three categories: healthcare, industrial and agricultural biotechnology. They will be showcased during a pitching session, followed by an awards ceremony hosted by Awards Jury Member and MEP Paul Rubig at the European Parliament in Brussels, Belgium on November 22.
The five shortlisted SMEs are:
Nightingale Health, a Finnish biotechnology company addressing chronic diseases with a proprietary blood analysis platform that can improve risk prediction of, among others, cardiovascular diseases and diabetes.
NovaBiotics, a UK-based clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
Carbios, a French green chemistry company focused on discovering and developing enzymatic bioprocesses to reinvent the lifecycle of plastics.
Numaferm, a German spin-off company from the Institute of Biochemistry of the Heinrich-Heine-University in Düsseldorf that has developed a reliable, cost-efficient technology to manufacture peptides based on well-designed microorganisms that convert simple nutrients to peptides.
Agricultural/ “Green Biotech” Category
Iden Biotechnology, a Spanish company developing biotech products and integrated solutions for crop yield and quality enhancement, including agrobiological products (e.g. plant biostimulants and biopesticides), and more productive crop varieties.
Visit the awards website to read more about the awards, the jury and the rules.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis
April 17th 2024Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.